Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Stability of Propranolol Hydrochloride in SyrSpend SF

Author(s):  Geiger Christine M, Voudrie Mark A II, Sorenson Bridget

Issue:  Nov/Dec 2012 - Volume 16, Number 6
View All Articles in Issue

Page(s):  513-515

Note:  Electronic version includes errata or revisions.

Stability of Propranolol Hydrochloride in SyrSpend SF Page 1
Stability of Propranolol Hydrochloride in SyrSpend SF Page 2
Stability of Propranolol Hydrochloride in SyrSpend SF Page 3

Download in electronic PDF format for $75

Abstract:  Propranolol hydrochloride is a beta blocker used to treat high blood pressure, abnormal heart rhythms, heart disease, pheochromocytoma, and certain types of tremors. Propranolol is marketed by Wyeth (now a part of Pfizer) and AstraZeneca under the brand names Inderal, Inderal LA, Avlocardyl, Deralin, Dociton, Inderalici, InnoPran XL, Sumial, Anaprilium, Bedranol SR (Sandoz). It is also available generically from several manufacturers. Propranolol hydrochloride is available as tablet, capsule, and oral liquid dosage forms in several strengths. Some patients are unable to tolerate oral tablets and capsules, challenging compounding pharmacies to seek alternative dosing options; namely oral solutions and suspensions. The objective of this study was to determine the stability of propranolol hydrochloride in SyrSpend SF. The drug was compounded into a 1-mg/mL suspension using SyrSpend SF and subsequently stored in a low actinic plastic prescription bottle at room temperature conditions. Six samples were assayed at each specific time point extending to 90 days by a stability-indicating high-performance liquid chromatography method. The method was validated for its specificity through forced-degradation studies. Based on the data collected, when protected from light at room temperature, the beyond-use date of propranolol hydrochloride in SyrSpend SF was shown to be at least 90 days.

Related Keywords: Christine M. Geiger, MS, Mark A. Voudrie II, MS, PMP, Bridget Sorenson, BS, CAPM, propranolol hydrochloride, nonselective beta-adrenergic receptor inhibitor, beta blocker, hypertension, high blood pressure, arrhythmias, heart disease, angina, tremor, chest pain, oral suspension, stability

Related Categories: EXCIPIENTS, PEER-REVIEWED, STABILITIES, COMPATIBILITIES, CARDIOLOGY, NEUROLOGY, STORAGE

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Stability of Propranolol Hydrochloride in SyrSpend SF
Geiger Christine M
, Voudrie Mark A II, Sorenson Bridget
Nov/Dec 2012
Pg. 513-515

Propranolol Hydrochloride 1 mg/mL in SyrSpend SF Oral Suspension
Allen Loyd V Jr
Jul/Aug 2018
Pg. 325

Propranolol Hydrochloride 1-mg/mL Injection
Allen Loyd V Jr
Jul/Aug 2014
Pg. 330

Stability of Ursodiol in SyrSpend SF Cherry Flavored
Geiger Christine M
, Voudrie Mark A II, Sorenson Bridget
Nov/Dec 2012
Pg. 510-512

Propranolol Hydrochloride Capsules
Allen Loyd V Jr
Nov/Dec 2015
Pg. 513

Stability of Verapamil Hydrochloride in SyrSpend SF Compared to Sorbitol Containing Syrup and Suspending Vehicles
Voudrie Mark A
, Alexander Bridget, Allen D Brett
May/Jun 2011
Pg. 255-258

Propranolol 2 mg/mL and 5 mg/mL in Ora-Blend SF Suspension
Allen Loyd V Jr
Mar/Apr 2022
Pg. 148

Stability of Gabapentin in SyrSpend SF
Sorenson Bridget
, Voudrie Mark A II, Gehrig Dan
Jul/Aug 2012
Pg. 347-349

Palonosetron Hydrochloride Compatibility and Stability with Three Beta-Lactam Antibiotics During Simulated Y-Site Administration
Ben Michel
, Trusley Craig, Kupiec Thomas C, Trissel Lawrence A
Nov/Dec 2007
Pg. 520-524

Stability Assessment of 10 Active Pharmaceutical Ingredients Compounded in SyrSpend SF
Geiger Christine M
, Sorenson Bridget, Whaley Paul
Sep/Oct 2015
Pg. 420-427

Compounded Beta-blocker Nasal Spray for Treatment of Acute Migraine: A New Therapeutic Modality
Hagan John C III
, Everett Eric, Chamberlain Tyler
May/Jun 2020
Pg. 194-197

Propranolol Hydrochloride 1-mg/mL Oral Liquid
Allen Loyd V Jr
Jul/Aug 2006
Pg. 304

A Compendium of Compounding Agents and Formulations, Part 5: Timolol and Beta-glucans
Riepl Mike
Sep/Oct 2022
Pg. 364-368

Stability of Captopril in SyrSPend SF
Geiger Christine M
, Sorenson Bridget, Whaley Paul A
Jul/Aug 2013
Pg. 336-338

Stability of Midazolam in SyrSpend SF and SyrSpend SF Cherry
Geiger Christine M
, Sorenson Bridget, Whaley Paul A
Jul/Aug 2013
Pg. 344-346

Propranolol 2 mg/mL or 5 mg/mL in Ora-Sweet
Allen Loyd V Jr
Nov/Dec 2021
Pg. 504

Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF pH4
Polonini Hudson
, da Silva Sharlene Loures, Brandão Marcos Antônio Fernandes, Bauters Tiene, De Moerloose Barbara, Ferreira Anderson de Oliveira
Nov/Dec 2018
Pg. 516-526

Infantile Hemangiomas, Part 2: Topical Treatment with Beta Blockers
Zur Eyal
Nov/Dec 2011
Pg. 458-463

Stability of Omeprazole in SyrSpend SF Alka (Reconstituted)
Whaley Paul A
, Voudrie Mark A II, Sorenson Bridget
Mar/Apr 2012
Pg. 164-166

Infantile Hemangiomas, Part 1: Treatment with Oral Propranolol Hydrochloride
Zur Eyal
Sep/Oct 2011
Pg. 358-366

Return to Top